Mechanical stretch induces podocyte hypertrophy in vitro

Kidney International

Volumn 67, Issue 1, 2005, Pages 157-166

  Petermann, Arndt T ^b   Pippin, Jeffrey ^b   Durvasula, Raghu ^b   Pichler, Raimund ^b   Hiromura, Eeiju ^b   Monkawa, Toshi ^b   Couser, William G ^b   Shankland, Stuart J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cell cycle; Cyclin dependent kinase; Hypertrophy; Kidney; Mechanical stress; Podocyte; Stretch

Indexed keywords

CYCLIN DEPENDENT KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL HYPERPLASIA; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; FOCAL GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; KNOCKOUT MOUSE; MECHANICAL STRESS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRETCHING;

EID: 10944270563     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00066.x     Document Type: Article

References (44)

1. NAGATA M, NAKAYAMA K-I, TERADA Y, et al: Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 153:1511-1520, 1998
2. PAVENSTADT H: Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol 278:F173-F179, 2000
3. KERJASCHKI D: Caught flat-footed: Podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 108:1583-1587, 2001
4. KRIZ W: Progressive renal failure-inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transplant 11:1738-1742, 1996
5. BARISONI L, MOKRZYCKI M, SABLAY L, et al: Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58:137-143, 2000
6. KRIZ W, GRETZ N, LEMLEY KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54:687-697, 1998
7. PREISIG P: What makes cells grow larger and how do they do it? Renal hypertrophy revisited. Exp Nephrol 7:273-283, 1999
8. TAMAMORI M, ITO H, HIROE M, et al: Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hyper-trophy. Am J Physiol 275:H2036-H2040, 1998
9. MORGAN DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291, 1997
10. 1-phase progression. Gene Dev 13:1501-1512, 1999
11. 1 phase cyclin-dependent kinases by mitogenic growth factors and the extracellular matrix. Cytokine Growth Factor Rev 8:165-170, 1997
12. 1 phase cell-cycle progression. Curr Opin Genet Dev 11:48-53, 2001
13. 1 phase cell cycle machinery. Bioessays 22:818-826, 2000
14. LAWLOR MA, ALESSI DR: PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114:2903-2910, 2001
15. ROUSE J, COHEN P, TRIGON S, et al: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78:1027-1037, 1994
16. KRIZ W, KRETZLER M, NAOATA M, et al: A frequent pathway to glomerulosclerosis: Deterioration of tuft architecture-podocyte damage-segmental sclerosis. Kidney Blood Press Res 19:245-253, 1996
17. PETERMANN AT, HIROMURA K, BLONSKI M, et al: Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 61:40-50, 2002
18. SHANKLAND SJ, PIPPIN J, FLANAOAN M, et al: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 51:1088-1099, 1997
19. WANO Y, HUANO S, SAH VP, et al: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273:2161-2168, 1998
20. AMANN K, KOCH A, HOFSTETTER J, et al: Glomerulosclerosis and progression: Effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60:1309-1323, 2001
21. ENDLICH N, KRESS KR, REISER J, et al: Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12:413-422, 2001
22. RISER BL, CORTES P, YEE J: Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens 9:43-47, 2000
23. CHAPMAN GB, DURANTE W, HELLUMS JD, SCHAFER AI: Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 278:H748-H754, 2000
24. VANDENBURGH H, KAUFMAN S: In vitro model for stretch-induced hypertrophy of skeletal muscle. Science 203:265-268, 1979
25. KOMURO I, KATOH Y, KAIDA T, et al: Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. Possible role of protein kinase C activation. J Biol Chem 266:1265-1268, 1991
26. CIP1) cause hypertrophy in LLC-PK1 cells. Kidney Int 56:494-501, 1999
27. MCKILLIGIN E, GRAINGER DJ: Cell volume and rate of proliferation, but not protein expression pattern, distinguish pup/intimal smooth muscle cells from subcultured adult smooth muscle cells. Cell Prolif 34:275-292, 2001
28. WAF/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56:1691-1699, 1999
29. WOLF G, SCHROEDER R, ZAHNER G, et al: High glucose-induced hypertrophy of mesangial cells requires p27(Kip1), an inhibitor of cyclin-dependent kinases. Am J Pathol 158:1091-1100, 2001
30. WAF1,CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 9:986-993, 1998
31. Waf-1 in vascular smooth muscle cells: Regulation of proliferation, differentiation, and cell size. Exp Mol Pathol 66:39-52, 1999
32. INOUAGGIATO P, GONZALEZ-MICHACA L, CROATT AJ, et al: Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. Kidney Int 60:2181-2191, 2001
33. HANNKEN T, SCHROEDER R, STAHL RAK, WOLF G: Angiotensin II-mediated expression of p27(Kip1) and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 54:1923-1933, 1998
34. BRAUN-DULLAEUS RC, MANN MJ, ZIEOLER A, et al: A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest 104:815-823, 1999
35. MONKAWA T, HIROMURA K, WOLF G, et al: The hypertrophic effect of transforming growth factor-beta is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27. J Am Soc Nephrol 13:1172-1178, 2002
36. LAVOIE JN, L'ALLEMAIN G, BRUNET A, et al: Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOG MAPK pathway. J Biol Chem 271:20608-20616, 1996
37. GILLE H, DOWNWARD J: Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 274:22033-22040, 1999
38. MUISE-HELMERICKS RC, GRIMES HL, BELLACOSA A, et al: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273:29864-29872, 1998
39. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neuoverexpressing cells. Nat Cell Biol 3:245-252, 2001
40. Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 275:39223-39230, 2000
41. DAVIES SP, REDDY H, CAIVANO M, COHEN P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105, 2000
42. HAQ S, CHOUKROUN G, KANG ZB, et al: Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151:117-130, 2000
43. PAP M, COOPER GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273:19929-19932, 1998
44. CROSS TG, SCHEEL-TOELLNER D, HENRIQUEZ NV, et al: Serine/threonine protein kinases and apoptosis. Exp Cell Res 256:34-41, 2000